

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/704,445	08/26/1996	BEN CHEN	202962001301	9201
1095	7590 02/03/2003			
THOMAS HOXIE NOVARTIS, PATENT AND TRADEMARK DEPARTMENT ONE HEALTH PLAZA 430/2 EAST HANOVER, NJ 07936-1080			EXAMINER	
			SHUKLA, RAM R	
Dist in iii	1151 111110 VER, 113 07950-1000		ART UNIT	PAPER NUMBER
			DATE MAILED: 02/03/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	08/704,445	CHEN ET AL.			
Advisory Addion	Examiner	Art Unit			
	Ram R. Shukla	1632			
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence address			
THE REPLY FILED 26 November 2002 FAILS TO PLACE Therefore, further action by the applicant is required to avoinal rejection under 37 CFR 1.113 may only be either: (1 condition for allowance; (2) a timely filed Notice of Appead Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applica) a timely filed amendment which	ation. A proper reply to a			
	EPLY [check either a) or b)]				
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this a no event, however, will the statutory period for reply expire to ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The ee have been filed is the date for purposes of determining the period of ee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of 2) as set forth in (b) above, if checked. Any reply received by the Offi imely filed, may reduce any earned patent term adjustment. See 37 C	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply ce later than three months after the mail	g date of the final rejection. HE FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension unt of the fee. The appropriate extension originally set in the final Office action; or			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered because:					
(a) X they raise new issues that would require further consideration and/or search (see NOTE below);					
(b) ☐ they raise the issue of new matter (see Note below);					
(c)	n better form for appeal by mate	rially reducing or simplifying the			
(d) they present additional claims without canceli	ng a corresponding number of fi	nally rejected claims.			
NOTE: <u>See Continuation Sheet</u> .					
3. Applicant's reply has overcome the following reject	ion(s):				
 Newly proposed or amended claim(s) would canceling the non-allowable claim(s). 	be allowable if submitted in a se	eparate, timely filed amendment			
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NOT place the			
6. The affidavit or exhibit will NOT be considered bec raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we					
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed: None.	·				
Claim(s) objected to: None.					
Claim(s) rejected: <u>1-3,5,8-14,17-19 and 21-40</u> .					
Claim(s) withdrawn from consideration: None.					
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Examiner.			
9. Note the attached Information Disclosure Statemen	nt(s)(PTO-1449)	·			
0.☑ Other: <u>See Continuation Sheet</u>					
·	RAM R. SHUKLA, PH.I PATENT EXAMINER	D Ram R. Shukla, Ph.D. Primary Examiner Art Unit: 1632			

U.S. Patent and Trademark Office PTO-303 (Rev. 04-01)

Continuation of 2. NOTE: Applicants cancelled claims 1-3, 5, 8-14, 17-19 and 21-40 and proposed new claims 41-59. Applicants have stated that the newly proposed claims encompass subject matter indicated as allowed by the previous Examiner in the office action of 5-12-1999. However, the newly presented claims do not represent the subject matter indicated as enabled in the above said office action. For example, claim 41 recites a method wherein the mammal substantially lacks functional endogenous B- and T- cells, however, the indicated office action stated that the mammal lacks functional endogenous B- and T-cells. Additionally, the enablement rejection had clearly indicated that applicants experiments in mice which lack all functional T- and B- cells is not correlative to treating mammals with functional T- and B- cells. Newly presented claims 44 and 45 encompass treating a mammaly with any immunodeficiency virus infection and HIV infection. Claim 43 encompasses xenogeneic transplantation. Other newly presented claims also encompass treatment mehtods in humans and other animals with B- and T- cells. The invention of such newly presented claims is not enabled. Therefore, even though the newly presented claims have narrower scope compared to claims rejected in the office action of 8-27-02, they raise new issues that will require further consideration and new search. Claim 56 has the word "efficiency" twice in line 1.

Continuation of 10. Other: It is noted that due to a clerical error the office action of 8-27-02 was indicated as non-final in the office action summary, however, as indicated in the office action on page 2, the action was made final.

RAM R. SHUKLA, PH.D PATENT EXAMINER